2016 Career Development Workshop for Biomedical Students · 2016 Career Development Workshop for Biomedical Students 1 2016 Career Development Workshop for Biomedical Students

2016 Career Development Workshop for Biomedical Students

1

2016CareerDevelopmentWorkshopforBiomedicalStudents

Planning Career Development

---Your Future Begins Now! Saturday,September24th,2016

HallofFlags,HoustonHall,3417SpruceStreet,PhiladelphiaPA,19104

Organizedby:Sino-AmericanPharmaceuticalProfessionalsAssociation-GreaterPhiladelphia

EventModulator: XueLiang

OrganizingCommittee: DavidCragin PatrickDeng YuGao

XueLiang YinLiang NanLin

AstonLiu FangShen BinShi

JiantingShi MengjieSi HaoSun

DiWu HaoWu ShuangWu

ZhenhuaWu JingYang HanghangZhang

JingyiZhang

ArtDesign: ShuangWu

BrochureEditing: JiantingShi MengjieSi HaoWu


2

Agenda

11:30AM-12:30PMCheck-in,LunchandNetworking12:30PM-12:45PMIntroductiontoSAPA-GP ZhenhuaWu,Ph.D.,AssociateDirectorandProgramLead,GlaxoSmithKlineDavidCragin,Ph.D.,AssociateDirector,ChemicalNotificationandRegistration,Merck&Co.12:45PM-1:15PMDeepUnderstandingofCareerOpportunitiesinPharmaceuticalIndustry JimWang,Ph.D.,M.B.A.,HeadofRegulatoryStrategy,SparkTherapeutics1:15PM-1:45PMWorkingLegallyinUSafterGraduation-aLawyer’sPerspective ValentineBrown,J.D.,Partner,DuaneMorrisLLP1:45PM-2:15PMCaseStudy:WhatYouReadfromaJobDescriptionandHowtoBuildTransferable

Skills

LarryPetcovic,M.S.,Co-Founder,SciPhD.com2:15PM-2:20PMBreak 2:20PM-3:55PMInteractivePanel:BringWhateverQuestionsYouMayHaveAllSpeakers3:55PM-4:00PMBreak 4:00PM-5:25PMRoundTableDiscussion

• TipsforJobHunting(Resume,Interview,Negotiation)

FangShen,Ph.D.,PrincipalScientist,JanssenRD,JohnsonandJohnsonXueLiang,Ph.D.,MicrobiomeScientist,Team/ProjectLead,MRLCambridge,Merck&Co.

• Communication&NetworkingSkillsLarryPetcovic,M.S.,Co-Founder,SciPhD.comDavidCragin,Ph.D.,AssociateDirector,ChemicalNotificationandRegistration,Merck&Co.

• R&DinthePharmaceuticalIndustry

YufengLi,Ph.D.,PrincipalClinicalResearchScientist,ClinicalPharmacologySciencesandStudyOperations,RDProjectsClinicalPlatforms&Sciences,GlaxoSmithKlineHuapingTang,Ph.D.,AssociatePrincipalScientist,BiologicsandVaccinesBioanalytics,Merck&Co.

• BusinessDevelopmentandSales&Marketing

PatrickDeng,M.B.A.,DirectorofFinance,IMSHealthChangXu,M.S.,SeniorManager,CommercialDecisionAnalysis,Pfizer

• IntellectualProperty&TechnologyTransfer

JimmyHao,Ph.D.,J.D.,RegisteredU.S.PatentAttorney,IntellectualPropertyDepartmentofFoxRothschildLLPHeatherA.Steinman,Ph.D.,M.B.A.,VicePresident,BusinessDevelopment&ExecutiveDirector,TechnologyTransfer,theWistarInstitute

• ImmigrationIssues

Jiazhong(Jason)Luo,Ph.D.,J.D.,Associate,DuaneMorrisLLPValentineBrown,J.D.,Partner,DuaneMorrisLLP

5:25PM-5:30PMClosingRemarksandRaffleDrawingFangShen,Ph.D.,PrincipalScientist,JanssenR&D


3

Biographies

ListedinAlphabeticalOrder

ValentineBrown,J.D.,Partner,DuaneMorrisLLP

Valentine A. Brown is a partner at Duane Morris LLP in the Employment, Labor,Benefits and Immigration Practice Group and is the Firm's Pro Bono Counsel. Sheserves as global immigration law counsel to a diverse group ofmulti-national anddomesticcorporationsandtheiremployees,providingadvice,complianceauditsandrepresentation to help navigate the intricacies ofUS and foreign immigration laws.Ms. Brown also represents individuals in all types of immigration proceedings,including persons of extraordinary ability; spouses, fiancées and children of US

citizens; naturalization and political asylum applicants; as well as respondents in deportation andimmigrationappellateproceedings.Sheisalsoamemberofthefirm'sCubaBusinessGroup.

Ms.BrownisaninstructorfortheDuaneMorrisInstitute,whichprovidestraininginallareasofemploymentlaw for human resource professionals, in house counsel, benefits administrators and managers throughclassesinPhiladelphia,client-sitetrainingsandwebinars.Ms.Brown'scoursesinclude,I-9ComplianceBasics;E-Verify for Everyone; E-Verify for Federal Contractors, Electronic I-9s: The Pros, the Cons and theRequirements;andH-1BPublicAccessFiles:WhatEmployersNeedtoKnow.

Ms.BrownisaformerlawclerktotheHonorableJohn.J.Gossart,ExecutiveOfficeforImmigrationReview,Baltimore, Maryland, a magna cum laude graduate of the University of Baltimore School of Law and agraduateoftheUniversityofDelaware.SheisfluentinSpanish.

Ms. Brown's practice focuses on Inbound and Outbound Temporary Visa Petitions; Permanent ResidencyApplications;CorporateImmigrationCompliance;andImmigrationLitigation.

David Cragin, Ph.D., Associate Director, Chemical Notification and

Registration,Merck&Co.

Dr. DaveCragin is theAssociateDirectorofChemicalNotificationandRegistrationforMerck& Co. Formore than 10 years, he has taught the graduate course called“Risk Assessment, Critical Thinking and Health” as an Adjunct Professor of HealthPolicyandPublicHealthfortheUniversityoftheSciences,Philadelphia.Since2008,hehasalso taughta subsetof thisclassasaProfessorof the InternationalProgram in

PharmaceuticalEngineeringManagementofPekingUniversity,Beijing,China. Inaddition,hehastaughtriskcommunicationintheUS,China,andEuropetobothindustryandregulatoryofficials.HespeaksChineseandis knowledgeable in many languages. Previously, he was the risk assessment manager and toxicologymanager for several companies in theoil, chemical, andpesticide industries.Dr. Cragin is aTrusteeof theToxicologyEducationFoundation, on theExecutiveBoardof theSino-AmericanProfessionalsPharmaceuticalAssociationGP,aPast-PresidentoftheMid-AtlanticSocietyofToxicology,thelargestchapteroftheSocietyof


4

Toxicology, and a Councilor for the PhiladelphiaAssociation forCriticalThinking. He received his Ph.D. inPharmacology andToxicology fromUniversityofCalifornia,Davis, his B.S. in Zoology from theUniversityofRhodeIsland,andisaDiplomateoftheAmericanBoardofToxicology.

PatrickDeng,M.B.A.,DirectorofFinance,IMSHealth

PatrickDeng is Director of Finance at IMSHealth, a leading global healthcare dataanalytics & technology services company. Patrick has over 16 years of strategy,planning,andoperationexperienceinfinanceandcommercialmanagement.

Inhiscurrentrole,Patrick is responsible forplanning/budgeting/forecastingof thecompany’skeyU.S.businesslines,newoffering&infrastructureinvestmentplanning,as well as acquisition integration reporting. He led the financial planning andinvestmentmanagementofaseriesofnextgenerationPharmacommercialanalytics

solutionofferings.

Priortohiscurrentrole,PatrickwasDirectorofFinance,StrategicPricing,atIMSHealth.Inthatcapacity,heled thedevelopmentandroll-outofnumerouspricing initiatives todriverevenueandprofitgrowth inU.S.andglobalmarkets.BeforejoiningIMSHealth,PatrickworkedinCorningIncorporatedinCorning,NewYork,wherehewasresponsibleforindustryresearch,demandforecast,andpriceplanningforitsTFT-LCDDisplaydivision.

PatrickobtainedhisMBAdegreeinFinanceandStrategicManagementfromtheWhartonSchool,UniversityofPennsylvaniaandhisBachelorofSciencedegreeinChemistryfromPekingUniversity.

Jianming Jimmy Hao, Ph.D., J.D., Registered U.S. Patent Attorney,IntellectualPropertyDepartmentofFoxRothschildLLP

Jimmy Hao is an attorney at law and registered U.S. patent attorney with theIntellectual Property (IP) department of Fox Rothschild LLP, a prominent nationalgeneralpracticelawfirm.Withmorethanadecadeoflegalexperience,heservesascounsel tomany clients including Fortune100 companies, startups, entrepreneurs,investors,andacademicinstitutionsinbiotechnologyandpharmaceuticalindustriesonabroadrangeofbusinessandlegalissues,includingpatent,trademark,licensing,litigation, VC financing, and M&A. He has prosecuted thousands of patentapplicationsnationallyandinternationally,includingportfoliosthatresultedinover

$47millionventurefinancingand$51.5millionacquisition.

Mr. Hao has provided legal representation to several notable business transactions, including AlexionPharmaceuticals Inc.’s acquisition of Synageva BioPharma Corp (valued at $8.4 billion), HumanwellHealthcareGroupandPuraCapPharmaceutical’sacquisitionofEpicPharma(valuedat$550million),BMS’sacquisition of Amira Pharmaceuticals (valued at $475million), licensing and collaboration deals involvingcompaniesincludingMerck,Alnylam,andothers.


5

Mr.Hao received a J.D. fromBostonCollegeLawSchool, a Ph.D. fromColumbiaUniversity, anM.B.A. fromCornell University, and a B.S. from Nankai University. Prior to his legal career, he conducted research onneural and heart development at Columbia University as a graduate student. During his time at ColumbiaUniversity,hisPh.D.thesiswasawardedwithDistinction.HelaterheldapostdoctoralfellowshipatHarvardMedicalSchoolwhereheconductedresearchononcology,immunology,andstemcells.

Yufeng Li, Ph.D., Principal Clinical Research Scientist, Clinical

Pharmacology Sciences and Study Operations, RD Projects Clinical

Platforms&Sciences,GlaxoSmithKline

Yufeng Li was awarded Ph.D. in translational cancer research at UTMD AndersonCancerCenterwherehepublished19scientificarticles,spoketwiceoninternationalcongress, obtained patent inventions in cancer immunotherapy and technologytransfer / businessdevelopment experience. YufenghasbeenwithGSK since2010

with project experience range from discovery biology, translational medicine to clinical development.Currently, Yufeng is responsible for clinical development programs in various therapeutic areas such asmetabolic, infectious disease, dermatology and oncology,with focus on experimentmedicine approach. AtGSK,Yufeng’sachievementhasbeenwellrecognized,tonameafew:#1inGSKVaccinesbusinesscompetitionon2012,exceptionalscienceawardon2015,2patentinventions.

Xue Liang, Ph.D., Microbiome Scientist, Team/Project Lead, MRL

Cambridge,Merck&Co.

Dr.XueLiangisaMicrobiomeScientistandaTeamLeadattheMRLCambridgeESC,LLC,asubsidiaryofMerck&Co.Herresearchfocusisontheinfluenceofmicrobiomeon host immunity and immune responses and its utilization in developing noveltherapeutics. Dr. Liang has >5 years of experience in microbiome research atUniversity of Pennsylvania and has published extensively in microbiome field on

PNAS,Cell, andeLife. Shehasbeenon theEditorialBoard for theFrontiers inPharmacologyandhasbeenguest speakers for symposiums, courses, and pharmaceutical companies. In addition, she has been anExecutive Board Member and a leading force for the Sino-American Pharmaceutical ProfessionalsAssociation-Greater Philadelphia (SAPA-GP) for the past three years, contributed significantly to thepromotionofpharmaceuticalsciencesandbiotechnologiesandtothecareerdevelopmentofpharmaceuticalprofessionals.Dr.LianghastaughtMandarinatDingHaoChineseSchoolformanyyears.ShereceivedherPh.D.inPharmacologyfromUniversityofPennsylvania,andB.S.degreeinbiologicalsciencefromZhejiangUniversity.


6

Jiazhong(Jason)Luo,Ph.D.,J.D.,Associate,DuaneMorrisLLP

Jiazhong(Jason)Luo,Ph.D.,practicesintheareaofintellectualproperty.Dr.Luohasmore than a decade of industry experience in materials science, chemistry andnanotechnologies, including research and development work and projectmanagement. He developed and commercialized several new technologies andproducts of polymers and nanomaterials, especially for electric, electronic,optoelectronic and semiconductor applications. He had working experience ininternational collaborationwith Japanesecompanies.Dr.Luo isan inventorofnineU.S.-issued patents and has five pending U.S. patent applications. He has also

authored15peer-reviewedresearchpapersandonelegalpaper.

Dr.Luohasrepresentedclients inpatentprosecutions in theareasof chemistry,material science,polymerscience,nanotechnology,semiconductors,optoelectronicmaterials&devices,pharmaceuticalcompositions,antibodyandbioanalysis.Hehasdraftedandprosecutedpatentapplicationsonpharmaceuticalcompounds,andhasperformedpatentability, freedom-to-operate,andduediligenceanalysesinthepharmaceuticalandmedicaldevicefields.Dr.Luo’spracticealsoincludespatentlitigationandinterpartesreview(IPR).

Dr.LuoearnedaPh.D.andaM.S.inMaterialsScienceandEngineeringfromTheOhioStateUniversity.Healsoholds aM.S. in Polymer Chemistry and Physics and a B.S. in Chemistry fromNankai University in Tianjin,China.Dr.LuograduatedfromTempleUniversityBeasleySchoolofLawwitha J.D.,cumlaude, in2013.Healso received the Robert C. Podwil Memorial Prize, which is awarded annually to the graduate whodemonstratesexcellentacademicperformanceandplanstopracticeintheareaofintellectualproperty.

HeisanativespeakerofChineseandspeaksfluentEnglish,andhasstudiedJapaneseandGerman.

LarryPetcovic,M.S.,Co-Founder,SciPhD.com

LarryPetcovicbrings25yearsofrichexperience inavarietyof industries;publiclyandprivatelyheldcompanies,midsize(100MM)andlarger(1.5B);inoperationalandstaff positions.His entrepreneurial spirit and startup experience bring a pragmaticapproach to his executive coaching techniques and his developing talent as in theSciPhD project of Human workflows. Larry is a Founder of 3rd OrderCommunicationsLLCandaCo-FounderofSciPhD.

HestartedhisprofessionalcareerasaHealthPhysicistandtransitionedintothetrainingofsciencesubjects.He thenmanagedall training forRylandGroupandspecialized in salesandcommunications impact.Larrythen pursued the GE workout process and directed process improvement programs for Ryland. Hetransitioned toassignmentsasVPofTrainingandVPCustomerServiceOperations forChevyChaseCreditCardOperations.IntheroleofVPHumanResources,hemanagedaleveragebuyoutofamanufacturingfirm.Throughout these roles, he continued to perform as Chairman of the Compensation Committee of a $100MillionNASDAQservicecompanyfor15years.

TheSciPhDprogramistheresultofthecombinationofLarry'smanyyearsofexperienceindevelopingandteachingsocialcommunicationsskillscombinedwithhisscientificandhumanresourcesindustryknowledgeandbestpractices.Larrycontinuestocoachindustryexecutivesinhighperformanceteamsandisaqualified


7

coach in several 360 and Leadership Effective Analysis type assessments. His work in behavioralcompetenciesisbasedonhiscurrentresearchinthesocialneurosciencesandsocialmediapractices.

LarryholdsaB.S.inChemistry,aM.S.fromRutgersUniversityinEnvironmentalRadiationSciences,anM.S.fromJohnsHopkinsUniversityinBehavioralSciencesanddoctoralworkinExecutiveDevelopmentatGeorgeWashingtonUniversity.Heisthecreatorofseveraluniqueteambaseddiagnosticexercisesandcontinuestowriteandexplorethesocialneurosciencesandstochasticdecisionmakinginexecutivecommunications.

FangShen,Ph.D.,PrincipalScientist,JanssenR&D,JohnsonandJohnson

Dr. Fang Shen is a Principal Scientist and project lead for multiple early drugdiscoveryprogramsinJanssenR&D,pharmaceuticalcompanyofJohnson&Johnson.Fangandhisteamareresponsibleforidentification&validationofnoveldrugtargets;understandingmolecular mechanism of drug action; and progressing pre-portfolioprojects into early development. Prior to that, Fangworked at Genentech for overtwo years as a key member of early drug discovery team. Dr. Shen got his

postdoctoral training inDr.SarahGaffen’s labatSUNYBuffalo,oneof the leadinggroupsonIL-17receptorbiology.HepublishedmultiplepapersonIL-17receptorconfiguration,signaltransduction,androleofIL-17inhostdefense.Dr.ShengothisPh.D.inInstituteofMateriaMedica,CAMS&PUMC(�� ),where he is one of themajor contributors of early stage research of Imrecoxib, anovelcyclooxygenase-2selectiveinhibitortotreatarthriticpainmarketedinChinain2011.

Heather A. Steinman, Ph.D., M.B.A., Vice President, Business

Development & Executive Director, Technology Transfer, the Wistar

Institute

Dr.SteinmanistheVicePresidentforBusinessDevelopmentandExecutiveDirector,Technology Transfer at TheWistar Institute. Dr. Steinman leads and oversees theimplementation of Wistar’s intellectual property strategy and all technologycommercialization activities, including licensing, start-ups, and collaborativeresearchanddevelopmentpartnerships.

Dr. Steinman has more than 18 years of experience in technology transfer andcommercialization of early stage, basic life sciences discoveries. She joined Wistar in 2014 from theUniversity of Pennsylvania,where shewasDirector of the PennCenter for InnovationPerelman School ofMedicine Office. Prior to that, Steinman played an essential role supporting the creation of new start-upsthrough Penn’s UPstart program in addition to her licensing and business development functions. BeforePenn, Steinman spent 10 years in various roles of increasing responsibility as a technology licensingprofessionalattheOfficeofTechnologyManagementfortheUniversityofMassachusettsMedicalSchool.

Steinman graduated Summa Cum Laude with dual degrees in biology and psychology from the honorsprogram at Baldwin-Wallace College. She holds a Ph.D. in Biomedical Sciences from the University ofMassachusettsMedical School and anM.B.A. from the Isenberg School ofManagement of theUniversity ofMassachusetts.


8

Huaping Tang, Ph.D., Associate Principal Scientist, Biologics and

VaccinesBioanalyticsdepartment,Merck&Co.

Huaping Tang is currently an Associate Principal Scientist in the Biologics andVaccines Bioanalytics department at Merck, where he focuses on developing,validating,andrunningbioanalyticalassaystosupportbiologicsandvaccinesclinicalstudies.Heisalsoresponsibleforevaluatingandimplementingnewtechnologiesforbiologicsandvaccinesbioanalysis.Prior to joiningMerck,Huapingspent5yearsattheLeadsDiscoveryandOptimizationdepartmentatBristol-MyersSquibb,wherehe

establishedatranslationalbiomarkerplatformtosupportinpreclinicalandclinicalbiomarkerstudies.Whileat BMS, he also led efforts in the area of complex and physiologically relevant cellular assays for leadoptimization.HuapinggothisPh.D.inMolecular,CellularandDevelopmentBiologyatYaleUniversity.HedidhisPost-doctoraltrainingattheNovartisInstitutesforBiomedicalResearchintheareaofoncologytargetedtherapy.

Jim Wang, Ph.D., M.B.A., Head of Regulatory Strategy, Spark

Therapeutics

JimistheheadofregulatorystrategyatSparkTherapeutics.HeobtainedhisPh.D.inchemistry from University of Illinois at Champaign-Urbana and a M.B.A. fromPennsylvania State University. Spark is a Philadelphia headquartered companydevelopingpotential one-time, life-altering gene therapies to transform the lives of

patients. Jim has more than 12 years of global regulatory experience managing full-spectrum drugdevelopment,marketingapplications,andregulatoryapprovalsforbiologics,genetherapy,smallmolecules,devicedrugcombinationproductsthatcoverophthalmology,cardiovascular,CNS,thrombosis,metabolic,andwomen’shealthareas.

Inhiscurrentrole,JimisleadingtheglobalsubmissionandapprovalforSPK-RPE65(voretigeneneparvovec)intended to treat rare blinding conditions caused by mutations in the RPE65 gene. He is managing theexecutionofregulatorymeetingswithglobalhealthauthorities,leadingthedevelopmentofcompanyproductlabel,riskmanagementplan,andregulatory filingdocuments.He isalso involved indefiningglobalmarketaccess strategy, establishing infrastructure to support global regulatory submission, approval, andcommercializationoftheproduct.

Priortohiscurrentrole,JimwasanexecutivedirectoratShirePharmaceuticals.Heledthedevelopmentandimplementation of consolidated global regulatory strategy to secure approval and market access for rarediseasebiologicalproductsthroughalldevelopmentphasesandlife-cyclemanagement.

Prior toShire, JimwasaseniordirectoratNovoNordiskbased inCopenhagen. He ledaglobal regulatoryteamandwasresponsibleformanaginginteractionsandnegotiationswithglobalhealthauthorities(e.g.FDA,EMA, PMDA, COFEPRIS, Health Canada, and China’s FDA), NDA/MAA/NDS submissions, and approvals forSAXENDA(liraglutide3mg)indicatedforweightmanagement.SAXENDAisnowapprovedgloballyinUS,EU,Brazil,andCanada.

Jim also worked as a director/global regulatory team leader in BMS leading the development of globalregulatorystrategy,healthauthorityengagementplan,targetlabeling,andglobalsubmissionplanforBMS


9

early and late stageproducts in themetabolic disease area. Prior toBMS, hewas an associatedirector inregulatorydevelopmentatSanofi.HeledtheFDAinteractionsforalatestagegenetherapyproduct,adevicedrug combinationproduct, aphase IICNSproduct intended for symptomatic treatmentofdementiaof theAlzheimertype,andcontributedtothesuccessfulpreparationofFDAadvisorycommitteemeetingsupportingthe approval forMULTAQ. He startedhis pharmaceutical career atWyethPharmaceuticals as aprincipalscientistinthedrugsafetymetabolismdepartmentandlatertransitionedtoregulatoryscience.

Zhenhua Wu, Ph.D., Associate Director and Program Lead,

GlaxoSmithKline

Dr.ZhenhuaWuisaseniordiscoveryandpreclinicaldevelopmentleaderwithmorethan15 years’ experience and adeepunderstandingof theR&Dvalue chain.He iscurrently an Associate Director in Neuroscience Therapeutic Area Unit atGlaxoSmithKline,whereheservesasaglobalprojectleaderfocusingontherapiesforneurodegenerative diseases. He is responsible for directing virtual drug discoverypipelinethroughpartneringwithexternalgroups,suchasbiotech,academicgroupsand CROs, toward to proof-of-concept studies. Prior to joining GSK, Zhenhua hadworkedinvariousfunctionalareasinMerck&Co.fornearly10yearswhereheled

various neuroscience projects and delivered three preclinical candidates and served as a globalexternalizationleaderinmajorgeographicregions.ZhenhuaisamemberoftheSocietyofNeuroscienceandholdsacertificateinRegulatoryAffairs.ZhenhuareceivedhisPh.D.degreeinneurosciencefromUniversityofRochesterandM.S.degreeincellbiologyfromShanghaiInstituteofCellBiology,ChineseAcademyofSciences.HehaspublishedextensivelyinthefieldofneuroscienceincludingpublicationsinprestigiousjournalssuchasNature,NatureMedicine,NeuronandStroke.HeisalsoarecipientofHughDavsonDistinguishedAwardinNeurovascular Biology. Zhenhua was recently elected to the President (2017-2018) of Sino-AmericanPharmaceuticalProfessionalAssociation–GreatPhiladelphia(SAPA-GP).

ChangXu,M.S.,SeniorManager,CommercialDecisionAnalysis,Pfizer

Changhas10years’richexperienceinPharmacyanalyticsinthepharmaceuticalandhealth insurance industries. Her experience includes promotional return onInvestment, pilot design and evaluation, brand strategy, forecasting, predictivemodeling, optimization, clinical trial, and health outcomes research. She currentlyworksasaSeniorManager inGlobalBusinessAnalyticsatPfizer.Beforeshe joinedPfizer,shewaspartoftheSpecialtyPharmacyAnalyticsteamatCigna.PriortoCigna,

she was a member of the US Commercial Decision Team at Eli Lilly, focusing on return on investment,optimization, pilot design and evaluation, and physician targeting.Changhas a Master’s degree inBiostatisticsfromUIC.


10

Notes

Documents

2016 Career Development Workshop for Biomedical Students · 2016 Career Development Workshop for Biomedical Students 1 2016 Career Development Workshop for Biomedical Students